Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma

Cancer Gene Therapy

Volumn 22, Issue 1, 2015, Pages 44-54

  Lathrop, M J ^a   Sage, E K ^b   Macura, S L ^a   Brooks, E M ^a   Cruz, F ^a,c   Bonenfant, N R ^a   Sokocevic, D ^a   MacPherson, M B ^a   Beuschel, S L ^a   Dunaway, C W ^d   Shukla, A ^a   Janes, S M ^b   Steele, C ^d   Mossman, B T ^a   Weiss, D J ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MESENCHYMAL STROMA CELL; MESOTHELIOMA; MESOTHELIOMA CELL LINE; MOUSE; NONHUMAN; PERITONEUM TUMOR; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BIOLOGICAL THERAPY; CELL MOTION; CELL PROLIFERATION; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION; GENETICS; LUNG NEOPLASMS; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; CYTOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; LUNG NEOPLASMS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MESOTHELIOMA; MICE; MICE, SCID; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR BURDEN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921868728     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.68     Document Type: Article

References (51)

1. Heintz NH, Janssen-Heininger YM, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol 2010; 42: 133-139.
2. Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ et al. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann NY Acad Sci 2010; 1203: 7-14.
3. Izzi V, Masuelli L, Tresoldi I, Foti C, Modesti A, Bei R. Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. Cancer Lett 2012; 322: 18-34.
4. Linton A, van Zandwijk N, Reid G, Clarke S, Cao C, Kao S. Inflammation in malignant mesothelioma - friend or foe? Ann Cardiothorac Surg 2012; 1: 516-522.
5. Shukla A, Gulumian M, Hei TK, Kamp D, Rahman Q, Mossman BT. Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. Free Radic Biol Med 2003; 34: 1117-1129.
6. Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009; 136: 888-896.
7. Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010; 18: 852-860.
8. Prockop DJ, Oh JY. Medical therapies with adult stem/progenitor cells (MSCs): a backward journey from dramatic results in vivo to the cellular and molecular explanations. J Cell Biochem 2012; 113: 1460-1469.
9. Corselli M, Chen CW, Crisan M, Lazzari L, Peault B. Perivascular ancestors of adult multipotent stem cells. Arterioscler Thromb Vasc Biol 2010; 30: 1104-1109.
10. Hodgkinson CP, Gomez JA, Mirotsou M, Dzau VJ. Genetic engineering of mesenchymal stem cells and its application in human disease therapy. Hum Gene Ther 2010; 21: 1513-1526.
11. Hong HS, Kim YH, Son Y. Perspectives on mesenchymal stem cells: tissue repair, immune modulation, and tumor homing. Arch Pharm Res 2012; 35: 201-211.
12. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012; 10: 709-716.
13. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012; 12: 383-396.
14. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, Prockop DJ. Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 2004; 103: 1662-1668.
15. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther 2012; 20: 14-20.
16. Porada CD, Almeida-Porada G. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Adv Drug Deliv Rev 2010; 62: 1156-1166.
17. Rebellato LM, Dobbs LJ Jr. Haploidentical transplantation. Importance of histocompatibility testing and chimerism studies in allogeneic bone marrow/stem cell transplantation. J Infus Nurs 2001; 24: 311-318.
18. Ciavarella S, Grisendi G, Dominici M, Tucci M, Brunetti O, Dammacco F et al. In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. Br J Haematol 2012; 157: 586-598.
19. Kim SM, Woo JS, Jeong CH, Ryu CH, Lim JY, Jeun SS. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886. Cancer Res 2012; 72: 4807-4817.
20. Kim SW, Kim SJ, Park SH, Yang HG, Kang MC, Choi YW et al. Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK. Clin Cancer Res 2013; 19: 415-427.
21. Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009; 69: 4134-4142.
22. Loebinger MR, Sage EK, Davies D, Janes SM. TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population. Br J Cancer 2010; 103: 1692-1697.
23. Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z et al. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther 2012; 19: 652-658.
24. Mueller LP, Luetzkendorf J, Widder M, Nerger K, Caysa H, Mueller T. TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. Cancer Gene Ther 2011; 18: 229-239.
25. Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM et al. Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ. J Breast Cancer 2012; 15: 273-282.
26. Holoch PA, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 2009; 625: 63-72.
27. Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel RA. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 2007; 6: 66.
28. Li Q, Verschraegen CF, Mendoza J, Hassan R. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer Res 2004; 24: 1327-1335.
29. Lee RH, Seo MJ, Pulin AA, Gregory CA, Ylostalo J, Prockop DJ. The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 2009; 113: 816-826.
30. Shukla A, Miller JM, Cason C, Sayan M, MacPherson MB, Beuschel SL et al. Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas. Clin Cancer Res 2013; 19: 2071-2083.
31. Toyooka S, Pass HI, Shivapurkar N, Fukuyama Y, Maruyama R, Toyooka KO et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001; 61: 5727-5730.
32. Hillegass JM, Blumen SR, Cheng K, MacPherson MB, Alexeeva V, Lathrop SA et al. Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int J Cancer 2011; 129: 233-244.
33. Zar JH. Biostatistical Analysis, 5th edn. Prentice-Hall/Pearson: Upper Saddle River, NJ, USA, 2010.
34. Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Butnor KJ et al. ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int J Cancer 2011; 129: 1075-1086.
35. Reagan MR, Kaplan DL. Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cells 2011; 29: 920-927.
36. Cyranoski D. Canada approves stem cell product. Nat Biotech 2012; 30: 571.
37. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012; 7: e47559.
38. von Bahr L, Batsis I, Moll G, Hägg M, Szakos A, Sundberg B et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012; 30: 1575-1578.
39. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012; 72: 3290-3301.
40. Ben-Ami E, Berrih-Aknin S, Miller A. Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev 2011; 10: 410-415.
41. Gregory LA, Ricart RA, Patel SA, Lim PK, Rameshwar P. microRNAs, gap junctional intercellular communication and mesenchymal stem cells in breast cancer metastasis. Curr Cancer Ther Rev 2011; 7: 176-183.
42. Sage E, Kolluri K, Giangreco A, Janes S. S60 Mesenchymal stem cells expressing TRAIL induce apoptosis in malignant pleural mesothelioma. Thorax 2011; 66 (Suppl 4): A29.
43. Hillegass JM, Shukla A, MacPherson MB, Lathrop SA, Alexeeva V, Perkins TN et al. Mechanisms of oxidative stress and alterations in gene expression by Libby six-mix in human mesothelial cells. Part Fibre Toxicol 2010; 7: 26.
44. Liu W, Bodle E, Chen JY, Gao M, Rosen GD, Broaddus VC. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol 2001; 25: 111-118.
45. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011; 71: 614-624.
46. Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R. New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol 2013; 182: 1065-1077.
47. Fan Y, Dutta J, Gupta N, Fan G, Gelinas C. Regulation of programmed cell death by NF-kappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol 2008; 615: 223-250.
48. Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood 2011; 118: 330-338.
49. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009; 37: 1445-1453.
50. Lee RH, Yoon N, Reneau JC, Prockop DJ. Preactivation of human MSCs with TNF-alpha enhances tumor-suppressive activity. Cell Stem Cell 2012; 11: 825-835.
51. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009; 27: 6237-6242.